be produced by autosensitisation with retinal proteins, and previous work has pointed to associations between circulating immune complexes and antiretinal autoimmunity in the human disease.""
In the preceding paper we describe in detail the ophthalmological features of 150 patients with idiopathic retinal vasculitis, 83 of whom had concomitant systemic inflammatory disease. In this paper we report on the occurrence of antiretinal antibodies and circulating immune complexes in this large group of patients. The study was undertaken to extend our earlier findings in a smaller group of patients' and to clarify whether these immunological criteria would discriminate patients with isolated retinal vasculitis (RV) from those with retinal vasculitis accompanying systemic inflammatory disease (RV+SID). An additional objective was to determine whether these immunological criteria, singly or together, would reflect the associated systemic disease or the form and severity of retinal inflammation.
Materials and methods

PATIENTS
Of the 150 patients described in the preceding paper3 a complete study of antiretinal antibodies (ret-AB) and circulating immune complexes (CIC) was obtainable in 142. Of these, two categories were specified: 63 patients had isolated retinal vasculitis (RV) and the remaining 79 had retinal vasculitis in association with systemic inflammatory disease (RV+SID). The latter category consisted of 38 patients with Behqet's disease (RV+Behqet's) and 14 patients with sarcoidosis (RV+sarcoid); the remaining 27 patients had other inflammatory diseases (RV+other SIDs), which included 11 with neurological abnormalities ('uveomeningitis group') and nine with seronegative polyarthritis, of which five were HLA B27-positive.3
MEASUREMENT OF ANTIRETINAL ANTIBODIES Two methods were used: passive haemagglutination (Hagg) and indirect immunofluorescence (11F). In the passive haemagglutination test bovine retinal-Santigen" was coupled to sheep erythrocytes with the aid of chromium chloride.7 Serial dilutions of patients' sera, in 20 ,ul volumes, were incubated in microtitre plates with equal volumes of 1% S-antigen coated red cells for two hours at room temperature, and the degree of haemagglutination was scored on a 4-point scale of + to + + + +. Antibody titre was expressed as the highest serum dilution giving definite (+) agglutination. In the indirect immunofluoresence test cryostat sections of snap frozen human retina were used as substrate. The tissue specificity of antiretinal immunofluorescence was established by reference to a standard polyclonal guineapig antiserum, raised against bovine S-antigen. Retinalspecific immunofluorescence was given by the photoreceptor layers of cones and rods, the cytoplasm of the outer nuclear layer, and the outer plexiform layer. A series of 57 sera from healthy control laboratory staff were examined by passive haemagglutination and by indirect immunofluorescence for the presence of antiretinal antibodies. By haemagglutination 53 of these sera had a titre of -1:8, and by immunofluorescence 50 were negative at a dilution of 1:5. Accordingly, the patients' sera were regarded as positive for antiretinal antibodies when these gave either a titre of , 1:32 by haemagglutination or a titre of 1:10 by immunofluorescence.
MEASUREMENT OF CIRCULATING IMMUNE COMPLEXES
Two methods were used: a polyethylene glycol (PEG) precipitation test and a Clq solid phase radiometric assay. In the PEG test the serum was precipitated with 2% polyethylene glycol and the IgG content of the precipitate was evaluated by radial immunodiffusion.'2 The Clq binding test was done by a modification of the method of Hay et al." Appropriately diluted sera were incubated in tubes coated with human Clq; immune complex levels were determined by subsequent reactivity with a ''21-labelled antiglobulin reagent, and the test was calibrated with aggregated human lgG. Our modification comprised the preincubation of Clq-coated tubes with nonlabelled rabbit antihuman IgG (Fcy), which helped to reduce the background uptake of labelled antiglobulin and to minimise false negative results in sera containing rheumatoid factors. Both PEG and Clq tests were validated in selected patients with renal, rheumatic, and haematological diseases, and in a large panel of healthy subjects. The following ranges of normal values were obtained: Clq-CIC, 20 6 (SD 2-6) mg IgG/l of serum; and PEG-CIC, 25 (SD 12) mg IgG/I of serum. CIC levels were deemed to be raised when the results were more than 2 SD above the normal mean: that is, when either the Clq test gave a value in excess of 25-8 mg IgG/l or the PEG test gave a value exceeding 49 mg IgG/l.
STATISTICAL ANALYSIS OF THE DATA
All clinical and immunological data were entered into a computer. Patients in the two major categories (RV alone, RV+SID), or in the three groups with concomitant systemic disease, or displaying defined ophthalmological criteria, were selected for comparative analysis of immunological and clinical features. Data Fig. 1 shows that by these criteria (see 'Methods') antiretinal antibodies were more prevalent in the sera of patients with RV+SID (63%) than those with RV alone (52%), but that in the latter category there were more patients whose sera were positive in both tests (22%) than in the RV+SID category (14%). Of the 57 normal sera also examined one gave a haemagglutination titre of -1:32 and a second was positive by immunofluorescence at a dilution of 1:10. In this study the prevalence of antiretinal antibodies in Table 3 and Fig. 2 show associations between antiretinal antibodies and raised levels of CIC in the total patient population, in the two major patient categories, and in the individual groups of the RV+SID category. When all patients were cdnsidered, 68% of those with raised levels of CIC also had antiretinal antibodies, while only 52% of the patients with normal CIC levels were antibody-positive (p=0066). In the RV+SID category 77% of CICpositive patients had antiretinal antibodies, while only 54% of CIC negative patients did so (p=0.036). In contrast, in patients with RV alone antiretinal antibodies were equally prevalent in patients with raised (56%) and normal (50%) levels of CIC (Table  3) . In all patient groups the proportion of positive sera reactive only for antiretinal antibodies was greater than the proportion of positive sera reactive only for circulating immune complexes (Fig. 2) . Thus in RV alone, of the 33 antibody-positive patients 19 (58%) were CIC-negative, while of the 25 CICpositive patients 11 (44%) were antibody-negative; and this pattern was reflected in the other patient groups (Fig. 2) . However, the proportion of sera within each patient group that contained both antiretinal antibodies and CIC together was similar (22-29%) with the exception of the RV group associated with SIDs other than sarcoid or Beh~et's disease, where it was somewhat higher (41%: Table 2 ).
Percentage positive sera reactive for AB or CIC only raised CIC levels (p=O 1, Table 5 ). Thus in the RV+ SID category there was evidence that certain patients with antiretinal autoimmunity and absent circulating immune complexes had severe retinal disease.
Of the 63 patients with RV alone only eight (13%) had severe retinal disease (DS>20 points), though the mean disease score of the 63 patients (11-6 (SEM 4-0)) was similar to that of the 78 patients with RV+ SID (mean: 11-5 (SEM 3.8)). In the 33 patients with RV alone who were antibody-positive (Table 2) there was no significant difference between the mean disease score of the 14 who were CIC-positive (14 5 Table 6 displays the prevalence of circulating immune complexes and antiretinal antibodies in relation to four principal features of retinal vasculitis in the whole series of patients, and it shows that there was a tendency for the individual features to be associated with antiretinal antibodies unaccompanied by circulating immune complexes.
Macular oedema. More than half (56%) of all the patients in the study had evidence of macular oedema. Antiretinal antibodies were found more frequently in patients with macular oedema (63%) than in those who had a normal macula (53%), though the difference was not statistically significant. However, as shown in Table 6 , there was a significantly lower incidence of raised CIC in patients with macular oedema in comparison with those with normal macula (p=0.023); and antiretinal antibodies were less frequently accompanied by CIC in these patients (p=0028: see Table 6 ). Periphlebitis and perivascular sheathing. Ninetyeight patients (69%) had one or both of these two clinical features. Of these patients 59% had antiretinal antibodies and 39% had raised CIC levels. The prevalence of these immunological features was the same as in the total population of 142 patients studied (see Table 2 ). There was a tendency for a higher frequency of CIC unaccompanied by retinal antibodies in the sera of patients with perivascular sheathing or periphlebitis (35%) in comparison with those without (22%).
Capillary closure and/or leakage. Eighty-seven patients (61%) had evidence of capillary closure or leakage as judged by fluorescein angiography. The prevalence of antiretinal antibodies (58%) and CIC (23%) in patients with these clinical features was not dissimilar to that in the total population of patients studied. There was a tendency for patients with capillary closure or leakage to have a higher frequency of antiretinal antibodies in the absence of CIC (61%) in their sera in comparison with those who did not have these retinal features (44%), where antiretinal antibodies tended to be more associated with CIC.
Vein occlusion or new vessels. These two clinical features were found in 40 patients only. The prevalence of antiretinal antibodies in the sera of these patients (59%) was the same as in the whole population studied, but raised CIC levels tended to occur less frequently (28%) in patients with vein occlusion or new vessels than in patients without these features (45%: p=0-068). The majority (65%) of antiretinal antibodies in the sera of patients with vein occlusion or new vessels were unaccompanied by raised levels of CIC, while antiretinal antibodies in patients without these features were equally distributed between CIC-positive and CIC-negative sera.
Discussion
In this paper we report on the prevalence of antiretinal antibodies and circulating immune complexes in 63 patients with isolated retinal vasculitis and 79 patients with retinal vasculitis accompanying systemic inflammatory diseases-data obtainable on 142 of the 150 patients whose clinical and ophthalmological features are described in the preceding paper.3 In extending our earlier work' we undertook this much larger study to determine whether patients with isolated retinal vasculitis (RV alone) would have a different immunological profile from those with retinal vasculitis accompanying systemic inflammatory disease (RV+SID) and to determine whether these immunological features would reflect the nature of associated systemic disease or the form and severity of retinal inflammation.
There have been a few reports concerning the presence of antiretinal antibodies in uveitis syndromes and these have stimulated some controversy.78`Thus in 1981 Gregerson's group8 reported a 60% prevalence of antibody to retinal S-antigen in a series of patients with a wide spectrum of uveitis; this finding was recently challenged by Doekes et a15 who used a similar immunochemical technique (ELISA) but could not discriminate between uveitis patients and normal controls, both of whom had the same prevalence (28-30%) of antibody to S-antigen. This study confirms our previous finding that both by immunofluorescence and passive haemagglutination antiretinal antibodies can be detected readily in patients with idiopathic retinal vasculitis' and reports that their prevalence in retinal vasculitis (58%) far exceeds that in normal individuals (3-5%).
It is likely that the prevalence of immunological abnormalities in uveitis syndromes depends both on the technique of detection and the clinical criteria on which the patient population is defined. Our previous finding of circulating immune complexes (CIC) in retinal vasculitis' was in accord with the findings of Char et aP on uveitis sera, and the prevalence of CIC in the present study (40%) provides further confirmation of this. We have accordingly proceeded to identify associations between the prevalence of antiretinal antibodies and circulating immune complexes A point prevalence study of150 patients with idiopathic retinal vasculitis in this larger series of patients with well characterised retinal vasculitis,3 with particular reference to the clinical interpretation of these immunological abnormalities.
In the present study a majority of the circulating immune complexes (CIC) were complement (Clq)-binding and very few sera were positive by both the Clq and PEG tests (Table 1 ). In all groups of patients the proportion of sera reactive only for antiretinal antibodies was greater than the proportion of sera reactive only for CIC (Fig. 2) , suggesting the greater relevance of autoimmune rather than immunecomplex mediated pathogenetic mechanisms. However, antiretinal antibodies tended to be more prevalent in CIC-positive sera (p=0-066, Table 3 ); and, while this association was dominated by the RV+SID category (p=0-036, When retinal disease score was also considered, the two major patient categories showed different patterns of association between the prevalence of antiretinal antibodies, CIC, and severity of retinal disease. Patients with RV alone, of disease score greater than 10 points, had a significantly higher prevalence of antiretinal antibodies than those with a lower disease score, while there was no such difference in the RV+SID category as a whole (Table 4) . The findings that, in RV alone, antiretinal antibodies were preferentially associated with CIC positivity in patients with the higher disease scores (Table 4) suggests that both antiretinal autoimmunity and circulating immune complex formation contribute to the pathogenesis of isolated retinal vasculitis. In terms of disease severity there appeared to be an additive effect of antiretinal antibodies and CIC together in RV alone, where patients with both immunological abnormalities had significantly more severe retinal disease than those with CIC only (p=0-010, Fig. 3 ). In contrast, the combination of both features in patients with RV+SID had no additive effect (p=0.014, Fig. 3 ).
Further analysis revealed that in RV+SID, patients who were positive for both antiretinal antibodies and CIC tended to have the lower mean retinal disease scores ( Table 5 ); and that in all three groups (RV+Behqet's disease, RV+sarcoid, RV+ other SIDs) those with antiretinal antibodies had higher mean disease scores if they were CICnegative. This was particularly true of the Behqet's disease group, where those who were antibodypositive, CIC-negative, had the highest prevalence of severe retinal vasculitis, with disease scores greater than 20 points (p=0028, Table 5 ). These findings reinforce our earlier proposition that, in certain patients with retinal vasculitis, CIC formation may indicate the operation of a protective (? anti-idiotypic) host response to antiretinal autoimmunity,' while in other patients CIC formation may add to the pathogenetic impact of autoimmunity on the retina.
The clinical relevance of studying antiretinal autoimmunity and circulating immune complexes in patients with retinal vasculitis would therefore appear to depend on the form of associated systemic disease and on the nature and occurrence of those features of retinal inflammation which contribute to disease severity in the individual patient. In isolated retinal vasculitis it seems that antiretinal antibodies are associated particularly with macular oedema and that the concomitant presence of circulating immune complexes and antiretinal antibodies is associated with more severe disease characterised in addition by perivascular sheathing and diffuse capillary leakage. In retinal vasculitis accompanying systemic inflammatory disease the most severely affected patients are antibody-positive despite anti-inflammatory and immunosupressive drug treatment. In Behqet's disease antiretinal antibodies may be absent; but, if they are present, the severely affected patient tends to be CIC-negative. Study of a larger group of RV patients with Behqet's disease would be required to determine whether retinal infiltrates, branch vein retinal occlusion and neovascularisation, macular oedema, and diffuse capillary leakage in this condition are specifically associated with one or other immunological profile. In RV accompanying sarcoidosis the most severely affected patients also have antiretinal antibodies unaccompanied by CIC. This finding suggests that periphlebitis and focal vascular leakage in retinal sarcoidosis have an autoimmune rather than an immune-complex pathogenesis. RV patients with other systemic inflammatory diseases, including the uveomeningitic syndrome, tended to have lower disease scores than patients with Behqet's disease or sarcoidosis; however, the most severely affected patients in this additional group were also those who had antiretinal antibodies in the absence of circulating immune complexes.
We conclude that the ophthalmological significance of studying antiretinal autoimmunity and non-tissue- 
